1. Home
  2. LOAN vs ANL Comparison

LOAN vs ANL Comparison

Compare LOAN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.78

Market Cap

51.9M

Sector

Real Estate

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$1.37

Market Cap

52.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
ANL
Founded
1989
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
51.9M
52.0M
IPO Year
1999
2023

Fundamental Metrics

Financial Performance
Metric
LOAN
ANL
Price
$4.78
$1.37
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
41.1K
10.1K
Earning Date
10-24-2025
11-07-2025
Dividend Yield
9.77%
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
$7,138,128.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$10.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.29
$1.10
52 Week High
$6.05
$2.99

Technical Indicators

Market Signals
Indicator
LOAN
ANL
Relative Strength Index (RSI) 48.78 33.11
Support Level $4.64 $1.32
Resistance Level $4.74 $1.59
Average True Range (ATR) 0.15 0.14
MACD 0.04 -0.01
Stochastic Oscillator 74.04 0.00

Price Performance

Historical Comparison
LOAN
ANL

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: